This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GRTX Galera Therapeutics (GRTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisNews and Trends About Galera Therapeutics Stock (NASDAQ:GRTX) Get Galera Therapeutics alerts:Sign Up Key Stats Today's Range$0.09▼$0.1150-Day Range$0.08▼$0.1052-Week Range$0.02▼$0.15Volume87,208 shsAverage Volume182,905 shsMarket Capitalization$14.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Galera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company focuses on developing precision medicines designed to address oxidative stress and inflammation in pulmonary and rare diseases. Galera’s proprietary platform centers on small-molecule prodrugs of glutathione and related thiol compounds intended to enhance intracellular antioxidant defenses. Galera’s lead product candidate is an inhaled glutathione prodrug currently in early-stage clinical trials for acute lung injury and acute respiratory distress syndrome. In addition to its pulmonary programs, the company is advancing research into supportive therapies for oncology patients and exploring additional indications where modulation of oxidative stress may offer therapeutic benefit. Galera employs both inhalation and systemic delivery approaches to optimize tissue targeting and pharmacokinetics. Founded in 2013, Galera has secured funding through private financings and a public listing on the NASDAQ under the symbol GRTX. The company collaborates with academic research centers and clinical investigators in the United States, and it is positioning itself for potential international partnerships to expand development and commercialization efforts. Under the guidance of a team of seasoned biotechnology executives and drug development scientists, Galera aims to translate its redox-modulating platform into new treatments for patients with high-unmet-need respiratory and systemic conditions.AI Generated. May Contain Errors. Read More Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRTX Stock News HeadlinesObsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 MillionAugust 3, 2026 | businesswire.comGalera Therapeutics Inc.May 19, 2026 | marketwatch.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.September 10 at 1:00 AM | Awesomely (Ad)Galera Therapeutics Eliminates Series B Preferred, Simplifies EquityMay 19, 2026 | tipranks.comMalvern-based Galera Therapeutics to be acquired in reverse mergerApril 16, 2026 | msn.comGalera Therapeutics to be acquired by Cambridge biotech firmApril 15, 2026 | bizjournals.comGRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its ShareholdersApril 14, 2026 | businesswire.comObsidian Therapeutics and Galera Therapeutics Announce Merger to Advance Engineered TIL Cell Therapies and Secure $350 Million FinancingApril 14, 2026 | quiverquant.comQSee More Headlines GRTX Stock Analysis - Frequently Asked Questions How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.15. When did Galera Therapeutics IPO? Galera Therapeutics (GRTX) raised $75 million in an initial public offering on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Verastem (VSTM) and Alerian MLP ETF (AMLP). Company Calendar Last Earnings11/10/2021Today9/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GRTX CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.64 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.08 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-99.34% Debt Debt-to-Equity RatioN/A Current Ratio9.74 Quick Ratio9.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.41) per share Price / Book-0.04Miscellaneous Outstanding Shares160,430,000Free Float47,375,000Market Cap$14.12 million OptionableOptionable Beta2.60 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:GRTX) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredThe Copper Race Is Coming Back To N. AmericaCopper demand is rising fast in 2026, driven by AI data centers, power grids, and electrification. Investors a...i2i Marketing Group, LLC | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts